Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cappuzzo, F. [1 ]
Moreno Garcia, V. [2 ]
Ou, S-H. I. [3 ]
Brandao, M. [4 ]
Sanmamed, M. F. [5 ]
Helissey, C. [6 ]
Wislez, M. [7 ]
Call, J. A. [8 ]
Grisanti, S. [9 ]
Johnson, M. L. [10 ]
Boni, V. [11 ]
Jamme, P. [12 ]
Monnet, I. [13 ]
Siena, S. [14 ]
Yan, C. [15 ]
Barasa, B. [16 ]
Richard, B. [17 ]
Joe, A. K. [18 ]
Laus, G. [18 ]
Felip, E. [19 ]
机构：
[1] IRCCS Ist Nazl Tumori Regina Elena IRE, Med Oncol, Rome, Italy
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[3] UCI Hlth Chao Family Comprehens Canc Ctr, Med Dept, Orange, CA USA
[4] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium
[5] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
[6] Begin Mil Teaching Hosp, Clin Res Unit, St Mande, France
[7] Hop Cochin AP HP, Paris, France
[8] South Texas Accelerated Res Therapeut START, Phase Trials, San Antonio, TX USA
[9] Univ Brescia, Med Oncol Dept, Brescia, Italy
[10] Sarah Cannon Res Inst, Lung Canc Res, Canc Ctr, Nashville, TN USA
[11] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[12] Ctr Hosp Reg Univ Lille, CHU Lille, Haut France, Lille, France
[13] CHI Creteil, Creteil, France
[14] Univ Milano Statale, UNIMI, Hematooncol Dept, Milan, Italy
[15] Merus NV, Biostat, Utrecht, Netherlands
[16] Merus NV, Translat Res, Utrecht, Netherlands
[17] Merus NV, Clin Operat, Utrecht, Netherlands
[18] Merus NV, Clin Dev, Utrecht, Netherlands
[19] Vall Hebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516MO
引用
收藏
页码：S1671 / S1671
页数：1
相关论文
共 50 条
  • [31] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    LUNG CANCER, 2024, 187
  • [32] Targeting β-catenin enhances the therapeutic efficacy of osimertinib in EGFR- mutant non-small cell lung cancer (NSCLC).
    Suman, Shankar
    Guan, Shu-Xiao
    Navari, Nastaran
    Arasada, Rajeswara Rao
    Carbone, David P.
    Memmott, Regan M.
    CANCER RESEARCH, 2021, 81 (13)
  • [33] First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
    Lorenzi, Martina
    Ferro, Alessandra
    Cecere, Fabiana
    Scattolin, Daniela
    Del Conte, Alessandro
    Follador, Alessandro
    Pilotto, Sara
    Polo, Valentina
    Santarpia, Mariacarmela
    Chiari, Rita
    Pavan, Alberto
    Dal Maso, Alessandro
    Da Ros, Valentina
    Targato, Giada
    Vari, Sabrina
    Indraccolo, Stefano
    Calabrese, Fiorella
    Frega, Stefano
    Bonanno, Laura
    Conte, Pier Franco
    Guarneri, Valentina
    Pasello, Giulia
    ONCOLOGIST, 2022, 27 (02): : 87 - E115
  • [34] OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer
    Tan, D. S. W.
    Amin, N.
    Madondo, M.
    Chapaneri, J.
    Tang, K. H.
    Taylor, R.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S338 - S339
  • [35] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Chen, Shen
    Zheng, Bin
    Yang, Jing
    Weng, Lizhu
    Liu, Mao-Bai
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
  • [36] Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
    Cardona, Andres F.
    Ruiz-Patino, Alejandro
    Recondo, Gonzalo
    Martin, Claudio
    Raez, Luis
    Samtani, Suraj
    Minata, Jose Nicolas
    Blaquier, Juan Bautista
    Enrico, Diego
    Burotto, Mauricio
    Ordonez-Reyes, Camila
    Chamorro, Diego F.
    Garcia-Robledo, Juan Esteban
    Corrales, Luis
    Zatarain-Barron, Zyanya Lucia
    Mas, Luis
    Sotelo, Carolina
    Ricaurte, Luisa
    Santoyo, Nicolas
    Cuello, Mauricio
    Mejia, Sergio
    Jaller, Elvira
    Vargas, Carlos
    Carranza, Hernan
    Otero, Jorge
    Rodriguez, July
    Archila, Pilar
    Bermudez, Maritza
    Gamez, Tatiana
    de Lima, Viadmir Cordeiro
    Freitas, Helano
    Russo, Alessandro
    Polo, Carolina
    Malapelle, Umberto
    Perez, Diego de Miguel
    Rolfo, Christian
    Viola, Lucia
    Rosell, Rafael
    Arrieta, Oscar
    CLINICAL LUNG CANCER, 2022, 23 (06) : 522 - 531
  • [37] Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
    Chamorro, D. F.
    Ruiz-Patino, A.
    Recondo, G.
    Martin, C.
    Raez, L.
    Samtani, S.
    Minata, J. N.
    Blaquier, J. B.
    Enrico, D.
    Burotto, M.
    Ordonez-Reyes, C.
    Garcia-Robledo, J. B.
    Corrales, L.
    Zatarain-Barron, L.
    Mas, L.
    Sotelo, C.
    Ricaurte, L.
    Santoyo, N.
    Cuello, M.
    Mejia, S.
    Jaller, E.
    Vargas, C.
    Carranza, H.
    Otero, J.
    Rodriguez, J.
    Archila, P.
    Bermudez, M.
    Gamez, T.
    de Lima, V. Cordeiro
    Freitas, H.
    Russo, A.
    Polo, C.
    Malapelle, U.
    de Miguel-Perez, D.
    Rolfo, C.
    Viola, L.
    Rossell, R.
    Arrieta, O.
    Cardona, A. F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S585 - S585
  • [38] Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
    Park, C.
    Cho, H.
    Choi, Y. D.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S492 - S492
  • [39] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Holleman, M. S.
    Al, M. J.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2018, 21 : S3 - S3
  • [40] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
12345